AFFILIATIONS
1 Monash Hospital and Monash University, Melbourne, Victoria, Australia, The Northern Hospital, Epping, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
2 The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
3 The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
4 The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
5 The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
6 The Royal Childrens Hospital, Parkville, Victoria, Australia, The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
7 The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
8 The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
9 The Alfred Hospital and Monash University, Melbourne, Victoria, Australia
10 The University of Queensland, Brisbane, Victoria, Australia
11 The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
12 The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
13 Austin Health, Heidelberg West, Victoria, Australia
14 Eastern Heath, Melbourne, Victoria, Australia
15 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
16 The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
17 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
18 The University of Melbourne, Parkville, Victoria, Australia, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
ABSTRACT
Introduction
NPM1 mutation (mut) is the commonest genomic variant in acute myeloid leukemia (AML) and generally associated with a favorable outcome. However, in older adults treated with conventional chemotherapy, this improved survival is less evident. We have previously shown that venetoclax (VEN) is highly effective at suppressing NPM1mut AML blasts as monotherapy (Chua et al, JCO 2020) and at eliminating NPM1mut MRD in combination with either chemotherapy or hypomethylating agents (DiNardo and Tiong, Blood 2020; Tiong et al, JCO 2024). We therefore sought to gain insight into the mechanism underlying NPM1mut sensitivity to VEN.
Methods
Single cell (sc) multiomic assessments (scDNA plus surface protein, Tapestri MissioBio; scRNAseq, 10x Genomics) were performed on patient serial samples with NPM1mut AML. NPM1 MRD was performed using RT-qPCR (sensitivity 10-6). Doxycycline inducible AML cells expressing NPM1 wild type (wt), NPM1mut, or transgenic NIBAN1. CRISPR/Cas9 gene editing in MOLM-13 cells to delete NIBAN1 and TP53.
Results
We conducted a sub-analysis of 20 patients with NPM1mut AML who received 5 days of infusional cytarabine and 2 days of idarubicin combined with up to 14 days of VEN (from Chua et al, JCO 2020). Despite this limited VEN exposure, bone marrow NPM1mut MRD was rendered negative in 71% and recurrence of NPM1mut at relapse observed in only 2 patients after a median follow-up of 38.6 months. In comparison, the frequency of bone marrow NPM1mut MRD clearance in an historical cohort (n=35) after intensive chemotherapy was only 20%.
Bone marrow examination after 7 days of VEN monotherapy pre-phase, prior to 5+2 induction, resulted in a 66% reduction in AML blasts, relative to baseline, along with a significant reduction in NPM1mut VAF. To explore the mechanism of enhanced sensitivity to VEN in NPM1mut AML, we generated syngeneic MOLM-13 AML cell line models permitting inducible expression of either NPM1mut or wt control. Enhanced VEN sensitivity was observed in cells expressing NPM1mut, but not NPM1wt. Moreover, improved sensitivity associated with NPM1mut was limited to VEN and not observed in response to an MCL1 inhibitor (S63845), cytarabine or an MDM2 inhibitor. We next selected a patient that rapidly extinguished NPM1mut MRD (by day 35), despite clinical progression with expansion of NPM1wt blasts. A multiomic approach was used to characterize the single-cell transcriptomic landscape of NPM1mut sensitive vs NPM1wt resistant cells. Parallel bulk RNA-seq studies were conducted on syngeneic MOLM-13 NPM1mut or wt cells and differentially expressed genes (DEGs) from patient and cell line models integrated. As expected, genes associated with NPM1mut AML (CTSG, HOXA9, MEIS1) were the top-ranked differentially overexpressed genes. In contrast, the top-ranked differentially underexpressed gene in NPM1mut cells was the stress response factor NIBAN1. Publicly available TCGA and BEAT-AML data confirmed reduced NIBAN1 gene expression in NPM1mut and also KMT2Ar, but not other sub-types of AML. In MOLM-13 cells induced to express NPM1mut, increased sensitivity to VEN was observed, with no further enhancement of VEN sensitivity following additional NIBAN1 deletion. In contrast, NPM1wt AML cells rendered NIBAN1 deficient demonstrated heightened sensitivity to VEN. NSG mice transplanted with MOLM-13 cells and treated with VEN survived longer when rendered deficient for NIBAN1 vs wt (p=0.001).
NIBAN1 has previously been reported to bind NPM1 in solid tumor cell lines and suppress p53 activity (Ji, EMBO Rep 2012). Using immunoprecipitation and mass spectrometry, we show that NIBAN1 binds not only to NPM1wt, but also to the NPM1mut protein. In contrast to TP53 proficient AML cells, no change in VEN sensitivity was observed following NIBAN1 deletion in MOLM-13 AML cells lacking TP53, suggesting that enhanced sensitivity to VEN conferred by NIBAN1 deficiency was TP53 dependent. Consistent with a role for NIBAN1 in restraining the level of expressed p53, we show that TP53 protein expression is enhanced in AML cells with depleted NIBAN1. The sub-cellular localization of NIBAN1 in NPM1mut vs wt cells is currently being explored.
Conclusion
VEN-based therapy potently suppresses NPM1mut AML, altering the natural history of the disease. Via sc-multiomic analyses, we show that NPM1mut is associated with reduced NIBAN1 gene expression. Deficient NIBAN1 enhances sensitivity to venetoclax in a TP53 dependent manner.